Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
REDWOOD CITY, Calif., Oct. 23, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its third quarter 2017 financial results will be released after market close on Monday, November 6th, 2017. Starting at 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing third quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.
Conference Call Information
When: November 6, 2017 at 4:30 p.m. ET
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 99333721
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar), CHS-0214 (etanercept biosimilar), and CHS-3351 (ranibizumab injection biosimilar) as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
